Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And we're very pleased with the partnership |
| We also have two differentiated clinical-stage assets and upcoming data readout on XMT-1660, and a strong balance sheet |
| We continue to be pleased, with the progress we're making in our Phase 1 trial of validating the safety and tolerability of XMT-1660 as a single-agent in patients with solid tumors, including triple negative and estrogen receptor positive breast cancer, as well as ovarian and endometrial cancers |
| And so when you think about what that means, it's about expanding what an ADC can do in the clinic and whether that's combinations or earlier lines to create very strong regimens |
| And third, we're striving to extend the field well beyond cytotoxics, and establish an entirely new class of ADC therapies that, elicit a targeted innate immune response to combat cancer |
| We have presented extensive preclinical data in the past demonstrating important advantages for Dolasynthen ADCs against ADCs produced using our own first-generation platform, Dolaflexin, and other platforms like vcMMAE |
| From a cash expenditure standpoint, we expect to continue realizing benefits, from these efforts in 2024 |
| Now while we're very excited about XMT-1660 and Dolasynthen, we believe IO may be the next significant frontier for ADCs |
| While we view our payload as a core differentiator and advantage |
| We believe the achievement of this goal could allow us to maximize the monotherapy potential of cytotoxic ADCs and also allow them to be used effectively in combination with other standard of care treatments, something that simply isn't possible with many of today's ADCs |
| And we show that our platform preclinically can deliver payload to the tumor much more efficiently and effectively |
| One of the things that we were very excited about from UpRi is, while overall, the response rate was lower, the - one of the things you'll see in the data is that the duration of response for those patients who did respond to UpRi was over seven months |
| So we think there's an opportunity to increase DOR |
| This platform has the potential to deliver a targeted and impactful 1-2 punch by activating STING in a target-dependent manner in tumor cells and in tumorresident myeloid and dendritic cells, while also minimizing the risk of systemic exposure |
| And one of the reasons we were pleased to see ESMO, from Seagen and from Hansoh at ESMO, the last data set, they showed no evidence of target-mediated toxicity |
| So we think that the landscape that's been established by that ESMO data disclosure leaves opportunity |
| So we think this meaningfully simplified cost structure is going to enable our available funds to support our operating plan commitments into 2026 |
| At Mersana, we're focused on bringing forward innovations, to address these limitations, to meaningfully improve the efficacy, and safety of ADCs |
| What takeaways can we use, from that to take forward and increase our confidence in the 1660 data, based on the new platform technology? Thanks |
| Brian Cheng Great |
| Brian Cheng Great |
| Brian Cheng Great |
| Good questions |
| With that as a backdrop, let's turn our attention to the progress, we're making in accomplishing these objectives |
| We think one of the advantages of having a locally tumor-directed STING agonist is that, that would allow you to do combinations with other systemic treatments |
| Good morning |
| Good morning |
| Good morning |
| Good morning |
| Asthika Goonewardene Good morning |
| Statement |
|---|
| Today, single-agent chemotherapy is the standard-of-care for these types of patients, and their prognosis is exceedingly poor |
| I think it's just going to be challenging to clearly demonstrate that in the initial data set |
| Although ADCs, have firmly established a position at the forefront of oncology, there are significant platform, and payload limitations that we believe, are preventing this therapeutic class from realizing its full potential |
| Net cash used in operating activities, was approximately $32 million for the fourth quarter of 2023, which is down significantly from prior quarters, thanks to our restructuring and UpRi wind-down efforts |
| With regards to data display, as Jason noted, we are in a highly competitive environment |
| One, I would like to put a little caveat on looking at duration of response in Phase 1 data sets even with pretty robust fulsome data sets is always challenging just because the number of responders to get a precise point estimate is always relatively limited |
| Mersana's net loss for the fourth quarter of 2023 was $19.5 million, compared to a net loss of $44.9 million, for the same period in 2022 |
| So again, I think it would be a little premature for us to pigeonhole ourselves into specific cuts of the data at this stage |
| We have two differentiated ADC platforms, platforms that we think could address, significant limitations for today's ADCs |
| But what that's associated with, and you think about it is, it's a slower clearance of the molecule because it has an antibody like half-life |
| The year-over-year decline in G&A expenses, was primarily related, to reduced consulting and professional fees, and reduced employee compensation as a result of the restructuring plan, we announced in July 2023 |
Please consider a small donation if you think this website provides you with relevant information